Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...
Why do some tumours spread while others remain localised? The mechanisms governing the metastatic potential of tumour cells remain largely unknown — yet understanding this is crucial for optimising ...
The Healthy @Reader's Digest on MSN
Here's how I knew I had colon cancer: One survivor's story after a single, subtle symptom
Colon cancer symptoms often don't exist. An active woman shares how repeated nudges from a loved one led to her diagnosis: "My entire life changed that day." ...
Liver transplant improved progression-free survival (PFS) in carefully selected patients with unresectable colorectal liver metastasis; however, the overall survival and recurrence rate benefits did ...
Automatic Classification of Tumor Response From Radiology Reports With Rule-Based Natural Language Processing Integrated Into the Clinical Oncology Workflow Pending validation in larger studies, ctDNA ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal approaches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results